Skip to main content

Market Overview

UPDATE: BMO Capital Markets Raises PT on Intercept Pharmaceuticals Following 2Q13 Operating Results

Share:

In a report published Wednesday, BMO Capital Markets analyst Jim Birchenough reiterated an Outperform rating on Intercept Pharmaceuticals (NASDAQ: ICPT), and raised the price target from $44.00 to $62.00.

In the report, BMO Capital Markets noted, “ICPT reported 2Q13 operating results today and provided an update on key initiatives. Loss per share of $0.79 was wider than consensus of $(0.51), primarily owing to a one-time non-cash charge, and ICPT ended 2Q13 with $162M, sufficient to fund operations through early 2016. No specific updates were provided on pipeline programs for lead bile acid analogue OCA, although ICPT will host a satellite symposium at the International Congress of Immunology on August 25, with focus on primary biliary cirrhosis (PBC). Our recent meeting with management at the BMO Capital Markets biotech corporate access day suggests that the POISE phase 3 study in PBC remains on track for data in 2Q14 and plans for expanded development in primary sclerosing cholangitis (PSC) and targeted development in portal hypertension are under review. Broader opportunity in NASH and bile acid diarrhea is also on track but precise timing of next data points is not yet clear.”

Intercept Pharmaceuticals closed on Tuesday at $46.08.

Latest Ratings for ICPT

DateFirmActionFromTo
Mar 2021HC Wainwright & Co.UpgradesSellNeutral
Mar 2021NeedhamMaintainsBuy
Mar 2021WedbushMaintainsOutperform

View More Analyst Ratings for ICPT
View the Latest Analyst Ratings

 

Related Articles (ICPT)

View Comments and Join the Discussion!

Posted-In: BMO Capital Markets Jim BirchenoughAnalyst Color Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
ICADGuggenheimInitiates Coverage On24.0
SMBKRaymond JamesUpgrades27.0
WNSNeedhamMaintains88.0
EFXNeedhamMaintains260.0
GOOGLJefferiesMaintains2,700.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com